Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Tamoxifen for Breast Cancer Prevention Has No Heart-Related Effects

May 1, 2001
Publication
Article
OncologyONCOLOGY Vol 15 No 5
Volume 15
Issue 5

Tamoxifen (Nolvadex) does not affect cardiovascular risk in healthy women or those with coronary heart disease, according to a study published in the Journal of the National Cancer Institute (93:16-21, 2001). The study is part of the National

Tamoxifen (Nolvadex) does not affectcardiovascular risk in healthy women or those with coronaryheart disease, according to a study published in the Journal of the NationalCancer Institute (93:16-21, 2001). The study is part of the National SurgicalAdjuvant Breast and Bowel Project’s Breast Cancer Prevention Trial.

"We found that cardiovascular event rates were notstatistically significantly different between women assigned to tamoxifen orplacebo, independent of preexisting coronary heart disease," said StevenReis, MD, principal investigator in the study, associate professor of medicineat the University of Pittsburgh School of Medicine, and director of the Women’sHeart Center at UPMC Health System’s Cardiovascular Institute. "Thesefindings should provide a degree of comfort to those women who are takingtamoxifen for breast cancer prevention."

Between 1992 and 1997, 13,388 women at increased risk for breastcancer were randomly assigned to receive tamoxifen or a placebo. After 4 years,13,194 women were available for cardiovascular follow-up, 1,048 of whom had aprior history of clinical coronary heart disease. The remaining 12,146 women hadno such history.

No Difference in Cardiovascular Events

The study found that women who had coronary heart disease whenthey entered the study had a higher rate of cardiovascular events than did womenwithout heart problems. However, within each group, there was no difference inthe rate of cardiovascular events between those receiving tamoxifen and thosereceiving a placebo.

There were 72 cardiovascular events among the 6,604 tamoxifenusers and 68 among the 6,590 women assigned to placebo. No differences werenoted in the incidence of fatal heart attack, nonfatal heart attack, unstableangina, or severe angina.

Among the 12,146 women without a history of clinical coronaryheart disease, there were 96 cardiovascular events—47 in the tamoxifen groupand 49 in the placebo group. Cardiovascular events for the 1,048 women with aprior history of clinical coronary heart disease also failed to show anystatistically significant differences between the treatment groups.

"Although the event rates in the group of women with aprior history of heart disease are greater than those observed in the group ofwomen without a history of heart disease, these data demonstrate that assignmentto tamoxifen did not affect cardiovascular events in this high-riskpopulation," said Dr. Reis. In this group, there were 25 cardiovascularevents in the tamoxifen group and 19 in the placebo group.

"Because tamoxifen is increasingly being prescribed for theprevention and treatment of breast cancer, longer-term clinical trials oftamoxifen in women are needed to further elucidate its long-term cardiovasculareffects," said Dr. Reis.

Articles in this issue

Current Therapy in Cancer, Second Edition
Health-Related Quality of Life in Cancer Clinical Trials
Paroxetine Reduces Distress Associated With Cancer Treatment
Another Attempt to Rein in Medicare
Tamoxifen for Breast Cancer Prevention Has No Heart-Related Effects
Exercise Benefits Patients Being Treated for Early-Stage Breast Cancer
Smoking Cessation Legislation
Transplant Registries: Guiding Clinical Decisions and Improving Outcomes
Comprehensive Breast Cancer Website
Study Confirms That Raloxifene Reduces Risk of Invasive Breast Cancer in Postmenopausal Women
New Approaches in the Management of Breast Cancer
Trends in Screening for Colorectal Cancer-United States, 1997 and 1999
Incidence and Management of AIDS-Related Lymphoma
Incidence and Management of AIDS-Related Lymphoma
Commentary (Bodurka-Bevers/Gershenson): Gynecologic Malignancies in Older Women
Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content
Advertisement

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

DCISionRT Shows Superiority vs Clinicopathology in Predicting DCIS Risk

Roman Fabbricatore
August 6th 2025
Article

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.

Gedatolisib Combos Improve PFS in Advanced PIK3CA Wild-Type Breast Cancer

Tim Cortese
July 29th 2025
Article

Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease

No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease

Ariana Pelosci
July 20th 2025
Article

Updated POSITIVE trial findings showed no significant breast cancer events in patients who breastfed following endocrine therapy for HR+ breast cancer.


The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
July 18th 2025
Article

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

Related Content
Advertisement

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.

DCISionRT Shows Superiority vs Clinicopathology in Predicting DCIS Risk

Roman Fabbricatore
August 6th 2025
Article

Patients reclassified to high-risk clinicopathology with DCISionRT saw an absolute reduction in IBR rates of 11.6%; from 17.7% to 6.1%.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.

Gedatolisib Combos Improve PFS in Advanced PIK3CA Wild-Type Breast Cancer

Tim Cortese
July 29th 2025
Article

Results from the phase 3 VIKTORIA-1 trial showed gedatolisib plus fulvestrant with or without palbociclib improved progression-free survival.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease

No Breast Cancer Events Noted When Breastfeeding After ET in HR+ Disease

Ariana Pelosci
July 20th 2025
Article

Updated POSITIVE trial findings showed no significant breast cancer events in patients who breastfed following endocrine therapy for HR+ breast cancer.


The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

T-DXd Granted Breakthrough Therapy Designation by FDA in HER2+ Breast Cancer

Roman Fabbricatore
July 18th 2025
Article

The regulatory decision is based on data from the phase 3 DESTINY-Breast09 results presented at the 2025 ASCO Annual Meeting.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.